This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synergy Pharmaceuticals Initiates Phase 2 Study Of SP-333 In Patients With Opioid-Induced Constipation

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) today announced the start of a phase 2 clinical trial to evaluate the safety and efficacy of SP-333, its second-generation GC-C agonist and once-daily oral treatment, in adult patients with opioid-induced constipation (OIC).

The multi-center, randomized, double-blind clinical trial will compare a 4-week, dose-ranging regimen of SP-333 (1.0, 3.0 and 6.0mg) against placebo in adult patients taking opioid analgesics for chronic, non-cancer pain for at least three months. The study plans to enroll approximately 260 patients with OIC who have less than 3 spontaneous bowel movements (SBMs) per week and who experience constipation-related symptoms. The primary endpoint of the study is mean change from baseline in the number of SBMs during Week 4 of the Treatment Period.

“Orally administered SP-333 has exhibited compelling data in preclinical models, demonstrating the ability to restore GI transit to normal levels and alleviate the onset of opioid-induced bowel dysfunction,” said Dr. Kunwar Shailubhai, Chief Scientific Officer, Synergy Pharmaceuticals Inc. “We are particularly excited with preclinical data that indicates SP-333 may be effective in treating methadone and morphine related constipation. Clinical validation of efficacy in methadone-induced constipation would be a breakthrough.”

“SP-333 marks Synergy’s second GC-C agonist in clinical development and represents another important milestone achieved this year in advancing our novel GC-C platform,” said Dr. Gary S. Jacob, Chief Executive Officer of Synergy Pharmaceuticals Inc. “Given SP-333’s favorable profile, we believe it has excellent potential to address the unmet needs of OIC patients. Beyond the OIC opportunity, we are continuing to develop a formulation of SP-333 to further explore its anti-inflammatory effect in patients with ulcerative colitis. We believe SP-333 is a very unique GC-C agonist with multiple pathways forward, expanding our ability to reach a broader market of patients in a variety of GI areas.”

About Opioid-Induced Constipation

Opioid-induced constipation (OIC) is a common condition affecting patients who receive opioid treatments to relieve pain. An estimated 12 million Americans are currently taking chronic opioids and over 90% experience some form of diminished bowel frequency. OIC is characterized by infrequent and incomplete evacuation of stool, hard stool consistency and straining associated with bowel movements. There is only one oral drug approved in the US to treat OIC but it is not approved for use in methadone-induced constipation.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%
TSLA $222.56 -4.20%
YHOO $36.00 -0.03%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs